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Abstract. The sequential endoproteolytic cleavages operated by the -secretase and the -secretase (BACE1) on the amyloid-
protein precursor (APP) result in the production of the amyloid- (A) species, with two C-terminal variants, at residue 40 or
at residue 42. Accumulation in brain tissue of small, soluble aggregates of A42 is the major pathogenic event of Alzheimer’s
disease (AD). However, the physiologic activity of A peptides is still elusive. Here, we show that expression of BACE1 is
regulated by A42, which augments BACE1 gene transcription through the JNK/c-jun signaling pathway. Of note, A40 has
much less effect on BACE1 expression. These findings unveil a positive feedback loop in which -secretase cleavage of APP
releases a functionally-active peptide, A42, that promotes BACE1 transcription. Thus, gene expression induced by A42 may
have implications in the neuronal dysfunction and degeneration that occurs in AD.
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INTRODUCTION
Accumulation in the brain of aggregates of
amyloid- peptides (A) is the major pathologic event
of Alzheimer’s disease (AD) [1]. A results from two
sequential endoproteolytic cleavages operated on the
amyloid- protein precursor (APP). The -secretase
(BACE1) cleaves the ectodomain of APP, producing
an APP C-terminal fragment that is further cleaved
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within the transmembrane domain by the -secretase,
resulting in the release of A peptides, with two
C-terminal variant, at residue 40 (A40) or at residue
42 (A42) [1]. The altered activity of both BACE1 and
the -secretase are involved in the pathogenesis of AD.
AD is classified into two forms: sporadic late-onset
AD, which is related to aging, and familial early-onset
AD (FAD), caused by gene mutations. Mutations of
presenilin 1 (PS1), the catalytic subunit of -secretase,
are the most common genetic defect of early-onset
familial AD and lead to an increased production of
A42 [2, 3].
Recently we reported that PS1 mutations expressed
in cells activates the expression of BACE1 [4]. The
expression and the activity of PS1 and BACE1 is aug-
mented in the brain of late-onset sporadic AD [5, 6].
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The cause of the altered APP processing and A42
overproduction in sporadic cases of AD is unclear, but
is likely to include oxidative stress.
We and other research groups have shown that
oxidative stress upregulates the expression of BACE1
through the activity of -secretase [7, 8]. Moreover we
showed that the presence of presenilins is necessary to
increase BACE1 expression under stress conditions [8,
9]. Now we investigated the pathway that mediates the
expression of BACE1 under oxidative stress.
MATERIALS AND METHODS
Cell culture, treatments, and transfection
SK-N-BE neuroblastoma cells were maintained
in RPMI (Roswell Park Memorial Institute) 1640
medium containing 2 mM glutamine and supple-
mented with 100 mL/L fetal bovine serum, 10 mL/L
non-essential amino acids, and 10 mL/L antibiotic
mixture (penicillin-streptomycin amphotericin), in a
humidified atmosphere at 37◦C with 5% CO2. For
differentiation, 2 × 106 cells were plated in 75 cm2 cul-
ture flasks (Costar, Lowell, MA, USA) and exposed to
10M retinoic acid for 10 days.
Mouse embryonic fibroblast (MEF) wt, PS1-/-,
PS2 -/-, PSdko (provided by Dr. Bart De Strooper,
Center for Human Genetics, Leuven, Belgium) [10],
APP+/APLP2-, APP-/APLP2+, APP/APLP2 dko
(provided by Dr. Ulrike Mueller, Max Plank Insti-
tute for Brain Research, Frankfurt, Germany) [11,
12], JNK1/2dko (provided by Dr. Roger Davis, Uni-
versity of Massachusetts, Worcester, Ma, USA) were
cultured in low glucose Dulbecco’s modified Eagle’s
medium containing 2 mM glutamine and supple-
mented with 100 mL/L fetal bovine serum, 10 mL/L
non-essential amino acids, and 10 mL/L antibiotic
mixture (penicillin-streptomycin amphotericin), in a
humidified atmosphere at 37◦C with 5% CO2.
Cells were incubated with 1M A peptides (40,
42 scramble, and 42, Anaspec, San Jose, CA, USA)
up to 6 h. The lyophilized commercial peptides were
dissolved as a stock solution in 1,1,1,3,3,3-hexafluoro-
2-propanol (Sigma Chemical Company, St Louis,
MO, USA) and stored at −80◦C in aliquots. The
desired amount was left under the cell culture hood to
allow for 1,1,1,3,3,3-hexafluoro-2-propanol to evap-
orate, brought to 1M with sterile double distilled
water and immediately added to the cells to avoid
aggregation. Twenty microliters of A preparations,
prepared as described in material and methods sec-
tion, were added to a carbon-coated Formvar grid
for 10 min, dried, and stained with 2% fosfotungstic
acid. Grids were examined by transmission electron
microscopy.
Cell permeable, JNK inhibitory peptide (Phoenix
Pharmaceuticals, Inc), at 2M, was added to MEFs
wild type cells at the time of A42 peptides [13].
APP reconstitution in MEF cells was performed
by transfecting a human APP 695 construct together
with pcDNA3.1, PS1 wt, PS2 wt, JNKwt and JNK
dominant negative (DN) using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instruc-
tions.
Transgenic mice
One-month-old male CRND8 mice, containing
a double mutation in the human APP gene
(K670M/N671 L and V717F) and C57bl/6 wild type
littermate were used. Genotyping of CRND8 mice was
performed by PCR, as described previously [14]. All
animal procedures were conducted according to the
ethical guidelines for treatment of laboratory animals
of Albert Einstein College of Medicine, Bronx, NY,
USA.
Tissue and cell extracts
Cytosolic and nuclear extracts of animal tissues were
prepared as described previously [15]. Briefly, cere-
bral tissues were homogenized at 10% (w/v) in a Potter
Elvehjem homogenizer (Wheaton, Millville, NJ, USA)
using a homogenization buffer containing 20 mM
HEPES, pH 7.9, 1 mM MgCl2, 0.5 mM EDTA, 1%
nonylphenyl-polyethylene glycol, 1 mM EGTA, 1 mM
dithiothreitol, 0.5 mmol/L phenylmethylsulfonyl flu-
oride, 5 mg/mL aprotinin, and 2.5 mg/mL leupeptin.
Homogenates were centrifuged at 1000 g for 5 min at
4◦C.
Supernatants were removed and centrifuged at
15,000 g at 4◦C for 40 min to obtain the cytosolic
fraction. The pelleted nuclei were resuspended in
extraction buffer containing 20 mM HEPES, pH 7.9,
1.5 mM MgCl2, 300 mM NaCl, 0.2 mM EDTA, 20%
glycerol, 1 mM EGTA, 1 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, 5 mg/mL aprotinin,
and 2.5 mg/mL leupeptin. The suspensions were incu-
bated on ice for 30 min for high-salt extraction
followed by centrifugation at 15,000 g for 20 min at
4◦C. The resulting supernatants containing nuclear
proteins were carefully removed and protein content
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was measured using a commercially available assay
(Bio-Rad, Segrate, Italy). Preparation of cell lysates
and nuclear extracts were performed as described pre-
viously [16, 17].
Antibodies and immunoblot analysis
The following antibodies were used: polyclonal anti-
BACE1 antibody (Chemicon, Temecula, CA, USA);
monoclonal  actin antibody and polyclonal lamin
A (Sigma Chemical Company); polyclonal anti PS1,
anti PS2, anti pAsk, anti Ask, anti pJNKK, anti
JNKK, anti pJNK and anti JNK, anti pc-jun, anti c-
jun antibodies (Cell Signaling Technology, Beverly,
MA, USA). Lysates and nuclear fractions extracts were
subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis on 9.3% acrylamide gels using
the mini-PROTEAN II electrophoresis cell (Bio-Rad).
Proteins were transferred onto nitrocellulose mem-
branes (Hybond-C extra Amersham Life Science,
Arlington Heights, IL, USA). Non-specific binding
was blocked with 50 g/L non-fat dry milk in 50 mM
Tris–HCl, pH 7.4, containing 200 mM NaCl and
0.5 mM Tween-20 (Tris-buffered saline Tween). The
blots were incubated with different primary antibodies,
followed by incubation with peroxidase-conjugated
anti-mouse or anti-rabbit immunoglobulins in Tris-
buffered saline Tween containing 20 g/L non-fat dry
milk. Reactions were developed with an enhanced
chemiluminescence system according to the manufac-
turer’s protocol (Amersham-Pharmacia Biotech Italia,
Cologno Monzese, Italy).
Analysis of gene expression
For the quantitative SYBR Green (2x iQ YBR
Green PCR Super Mix; Bio-Rad Laboratories) real-
time PCR, 40 ng of cDNA was used per reaction.
RNA extraction was performed with the RNeasy kits,
according to the manufacturer’s protocol, for cell
lines and brain tissue (Qiagen, CA, USA); cDNA
was obtained with the SuperScript® III CellsDi-
rect cDNA Synthesis Kit (Invitrogen, CA, USA).
Primer sequences, designed with PRIMER 3 software
(Applied Biosystems, Monza, Italy) were:
Human BACE1 : 5′-CATTGGAGGTATCGACCA
CTCGCT-3′ and 5′CCACAGTCTTCCATGTCCAAG
GTG-3′.
Human  actin: 5′-GGCACTCTTCCAGCCTTC
CTTC-3′ and 5′-GCGGATGTCCACGTCACACTT
CA-3′.
Murine BACE1 : 5′-GCATGATCATTGGTGGTA
TC-3′ and 5′-CCATCTTGAGATCTTGACCA-3′.
Murine  actin: 5′-AGCTATGAGCTGCCTGACG
GC-3′ and 5′-CATGGATGCCACAGGATTCCA-3′.
Quantitative PCR was performed on a real-time
iCycler sequence detector instrument (Bio-Rad Lab-
oratories). After 3 min of initial denaturation, the
amplification profile included 30 s denaturation at
95◦C and extension at 72◦C. Primer annealing was
carried out for 30 s at 60◦C. The results were obtained
with the comparative Ct method using the arithmetic
formula 2−Ct. Samples obtained from at least three
independent experiments were used to calculate the
mean and SD.
Run-on assay
MEFs as well as SK-N-BE differentiated neuroblas-
toma cells (6×106) were lysed in 200l lysis buffer
(10 mM NaCl, 3 mM MgCl2, 10 mM Tris-HCl, pH 7.4,
0.5% Nonidet-P40) and briefly centrifuged. Nuclei
were then stored at −80◦C in a storage buffer consist-
ing of 40% glycerol, 50 mM Tris-HCl, pH 8.5, 5 mM
MgCl2, and 0.1 mM EDTA. Pipetting should be done
with a wide-bore pipet tip to avoid breaking nuclei
obtained.
To 50l of nuclei, 50l of reaction buffer contain-
ing radiolabeled nucleotide (50 Mm HEPES, pH 7.5,
5 mM MgCl2, 5 mM DTT, 150 mM KCl, 10% glycerol,
2.8 mM ATP, 2.8 mM GTP, 2.8 mM CTP, 3.2 mM UTP,
40Ci of {32P}UTP (Amersham-Pharmacia Biotech
Italia, Cologno Monzese, Italy)) were added and the
samples were incubated at 30◦C for 10 min with shak-
ing. RNA was then extracted from the nuclear run-on
reaction using Trizol (Invitrogen) according to manu-
facturer’s protocol.
Transcripts obtained were quantified by hybridiza-
tion to nitrocellulose strips, containing BACE1 cDNA
(1g each) immobilized using a dot blot apparatus,
at 42◦C for 72 h. Before hybridization, the mem-
branes were prehybridized using a hybridization buffer
consisting of 50% formamide, 6 × SSC, 10X Den-
hardt’s solution and 0.2% SDS for at least 6 h at
42◦C. After hybridization strips were washed once
with 6xSSC and 0.2% SDS at room temperature for
10 min, then twice with 2x SSC and 0.2% SDS, fol-
lowed by two washes in 0.2x SSC and 0.2% SDS, all
at 65◦C for 10–30 min each wash. The strips were then
exposed to Kodak hyperfilms (Amersham-Pharmacia
Biotech Italia, Cologno Monzese, Italy) at −80◦C for
4 days. Band intensity was determined by scanning
densitometry and the level of each BACE1 mRNA was
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normalized to the levels of RNA obtained by nuclei
supernatants (saved for RNA isolation).
Enzyme-linked immunosorbent assay
The levels of Ax−40 and Ax−42 were measured by
sandwich ELISA method following the manufacturer’s
instructions (IBL, Gunma, Japan). Samples were ana-
lyzed following the manufacturer’s instructions. The
A concentration was detected using a Benchmark
Microplate Reader and evaluated by ‘microplate man-
ager’ v. 5.1 software (Bio-Rad). ELISA analysis of all
samples was performed in two different experiments.
Activator protein 1 (AP-1) transcription factor
determination
The activity of AP-1 was determined by a com-
mercially available kit (Active Motif), designed
specifically to detect and quantify AP-1 activation.
The kit contains a 96-well plate to which oligonu-
cleotide containing a TPA-responsive element (TRE)
has been immobilized. AP-1 dimers contained in
nuclear extracts bind specifically to this oligonu-
cleotide and are detected through use of an antibody
direct against c-fos, fosB, fra-1, fra-2, c-jun, junB,
junD. Addition of a secondary antibody conjugated
to horseradish peroxidase (HRP) provides sensitive
colorimetric readout that is easily quantified by spec-
trophotometry.
RNA interference
The mouse retroviral shRNA c-jun and the non-
silencing shRNA sequence, that was expressed under
the control of the U6 promoter and contains no homol-
ogy to known mammalian genes, were purchased by
Open Biosystems. The cells were harvested 48 h after
shRNA transfection before samples preparation.
Statistical analysis
Data in bar graphs represent mean ± SEM, and
were obtained from average data of at least three
independent experiments. Morphological images are
representative of at least three experiments with similar
results. Statistical analysis was performed by Student’s
t-test or ANOVA, followed by the Bonferroni post
test, when appropriate (p < 0.05 was considered sig-
nificant).
RESULTS
Aβ42 activates the transcription of BACE1 in
different experimental models
We have recently shown that the activity of the -
secretase are required to obtain the upregulation of
BACE1 mediated by oxidative stress [8]. Moreover,
we found that PS1 mutations augment the expression
of BACE1 by altering the activity of the -secretase
[4].
The APP derivatives that results from the -
secretase cleavage are the A peptides and the APP
intracellular domain (AICD). We investigated which
derivative is responsible for BACE1 upregulation. We
first analyzed the effect of the AICD fragments 57 and
59, the APP derivatives resulting from the  cleavage
of APP, as well as AICD 50 and 51 that are the 
cleavage derivatives [18–20]. Transfection of different
cell lines, such as SK-N-BE, SH-SY5Y, and HEK-293
with the corresponding AICD constructs determined
no changes of BACE1 expression (data not shown) [see
4]. The above experiments ruled out the role of AICD
in the overexpression of BACE1 and pointed to the
other derivative of the -cleavage, the A peptides. We
have previously observed that A42 increase BACE1
expression in primary neuronal cultures [4]. The data
of the present study confirm and extend our results
using different experimental models. We first studied
whether A peptides may function in gene expression
by using a run on assay. We used MEFs knock out cells
for PS1 and PS2 [10] and for APP or APP-like pro-
tein 2 (APLP2) (APP+/APLP2-) (APP-/APLP2+),
as well as MEFs APP/APLP2 dko [21, 22]. We incu-
bated MEFs PSdko and APP/APLP2 dko with A40
and A42 synthetic peptides, at a concentration of
1M, fresh preparation. The aggregation state of syn-
thetic A preparations was examined with electron
microscopy and no fibrillar or oligomeric structures
were detected (data not shown).
MEFs PS dko and APP/APLP2 dko were incu-
bated with A42 and A40, and the amount of nascent
RNA was serially evaluated from 5 min until 1 h. In
both MEFs dko cells treated with A42, there was
a time-dependent increase in BACE1 nascent RNA,
reaching a peak of 5 fold increase at 1 h, compared
to non treated cells (Fig. 1A–D). Incubation with
A40 did not change the amount of BACE1 nascent
RNA (Fig. 1A–D). Incubation of MEFs PS dko and
APP/APLP2 dko with A42 was followed by a sig-
nificant increase (approx. + 100%) of BACE1 protein
levels after 12 h of incubation (Fig. 1E–H).
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Fig. 1. Effect of A peptides on BACE1 transcription and expression in MEF cells. A–D) Run on assay. Nascent RNA of BACE1 increased
by 3.5–4 fold in MEFs PSdko (A, C) and in MEFs APP/APLP2 dko (B, D) when incubated with 1M A42 peptide. Treatment with A40
did not change BACE1 nascent RNA. E–H) Treatment of MEFs PSdko (E, G) or MEFs APP/APLP2 dko (F, H) with 1M A42 peptide was
followed by a significant increase in BACE1 protein levels after 3 hours up to 12 h. The error bars represent standard deviations. Experiments
were conducted in triplicate. *significantly different from controls (p < 0.05). **significantly different from controls (p < 0.02).
Then, we confirmed the role of A peptides on
the upregulation of BACE1 in differentiated SK-N-BE
neuroblastoma cells. We treated differentiated neurob-
lastoma cells with A42 scramble, A40, A42, or
medium only, up to 6 h. A42 determined an increase
in BACE1 mRNA production (3 fold increase) after 1 h
of incubation (Fig. 2A) and in BACE1 protein levels
(+120%) after 6 h of incubation (Fig. 2B, C). Incuba-
tion with the scramble peptide or A40 did not change
neither the amount of BACE1 mRNA nor BACE1 pro-
tein levels (Fig. 2A–C). Furthermore, we performed a
run on assay to evaluate the function on gene expres-
sion of A peptides in this cellular model. As expected,
cells treated with A42 showed a significant increase
in BACE1 nascent RNA (2.3 fold increase) after 1 h of
incubation, compared to non treated cells (Fig. 2D,
E). Incubation with the scramble peptide or A40
did not change the amount of BACE1 nascent RNA
(Fig. 2D, E).
Then we ascertained the effect of A42 on the
expression of BACE1 in vivo, using double mutant
APP transgenic mice (KM670/671NL + V717F) [14]
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**significantly different from controls (p < 0.02).
as model of early A42 overproduction and accumu-
lation. As reported in Fig. 3A, 1-month-old CRND8
transgenic mice presented significantly higher cerebral
levels of total A42 (+65%) than non transgenic litter-
mate. Of note, levels of total A40 are very similar in
both transgenic and non transgenic mice (Fig. 3A). The
CRND8 1-month-old transgenic mice also presented a
3 fold higher expression of BACE1 (Fig. 3B) as well as
a significant increase (+100%) in BACE1 protein levels
(Fig. 3C, D) with respect to non transgenic littermates.
The JNK/c-jun pathway mediates the
transcriptional activity of Aβ42
We investigated the mechanism of the transcrip-
tional activity operated by A42. The c-jun N-terminal
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kinase (JNK) signaling pathway is a potential player of
this role, since it is activated by A peptides [23–26].
MEFs wild type incubated with A42 showed the
activation of JNK, and of the kinases that belong to
the pathway of JNK signaling, the apoptosis signal-
regulating kinase 1 (ASK-1), the jun kinase kinase
(JNKK), and c-jun (Fig. 4A). Then, we tested if the
JNK pathway was activated in SK-N-BE differentiated
neuroblastoma cells. As reported in Fig. 4B, incubation
of cells with A42 was followed by a robust activation
of JNK and c-jun, as shown by the increased levels of
phospho-JNK and phospho c-jun in SK-N-BE nuclear
fractions (Fig. 4B).
Figure 4C shows the nuclear protein levels of JNK
and c-jun phosphorylated forms in transgenic or not
transgenic CRDN8 mice. The elevation of both JNK
and c-jun isoforms was observed in transgenic mice as
compared to control mice.
To further ascertain the role of JNK in the activa-
tion of BACE1, we incubated MEFs JNK1/2 dko with
A42. Of note, in the MEFs JNK ko the basal expres-
sion of BACE1 is much lower than in wild type cells
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Fig. 4. JNK pathway activation in our experimental models mediated by A42 peptide. A) A42 activates the JNK pathway in MEFs wild type
up to 6 h. B) Significant increase in phosphorylation of JNK and c-jun after treatment of SK-N-BE differentiated cells with 1M A42 peptide.
C) JNK and c-jun phosphorylated isoforms are higher in 1-month-old CRND8 transgenic mice respect to non transgenic littermates.
(Fig. 5A, B) and incubation with A42 did not change
the expression of BACE1. Remarkably, transfection
with JNK wild type, but not with a JNK dominant neg-
ative construct (Fig. 5C, D), reconstituted the effect of
A42 on BACE1 expression.
Finally we tested the role of the transcription factor
activator protein 1 (AP-1), the transcriptional ele-
ment of the JNK signaling pathway. AP-1 is formed
by proteins of the jun, fos and ATF families that
become active upon homo- and heterodimerization.
JNK activates AP-1 by phosphorylating c-jun [27]. In
Fig. 5E is reported that A42 treatment resulted in a
significant increase in c-jun and c-fos DNA binding
activity.
To inhibit the activation, we silenced c-jun with the
RNA interference technique. The inhibition of c-jun
blocked the increase of BACE1 protein levels induced
by A42 (Fig. 6A, B).
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Fig. 5. Role of JNK signalling pathway on the transcription of BACE1. A, B) MEFs JNK1/2 dko had low basal levels of BACE 1 and were
resistant to the effect of A42 on BACE1 expression. C, D) Transfection of MEFs JNK ko with JNK, but not with JNK dominant negative (DN),
restores the upregulation of BACE1 protein levels induced by A42. E) A42 treatment induce the activation of AP-1 transcription factor, showed
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triplicate. *significantly different from controls (p < 0.05). **significantly different from controls (p < 0.02).
Then, we treated MEFs wild type with a cell
permeable, selective JNK inhibitory peptide (13).
JNK inhibition prevented the up-regulation of BACE1
expression by A42 (Fig. 6C, D).
DISCUSSION
Our study reveals a novel effect function of A pep-
tides. We demonstrated that A42 is the player of a
positive feedback loop from the -secretase cleavage
on the -secretase cleavage of APP. Thereby, A
might play a role not just as a toxic molecule, but as
a functional signaling intermediate. Previous studies
have proposed different physiological functions of A
[28, 29]. The more convincing clue finding came from
the study of Kamenetz et al. [30], indicating A as
the player of a negative feedback loop that regulates
the synaptic activity. Accordingly, A production is
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proportional to the level of brain activity, as shown
in the recovery from severe cranial trauma [31]. Taken
together these data argue that A is closely related with
synaptic activity and may provide a physiological con-
trol on synaptic activity, protecting against excessive
glutamate release. On the basis of our results, it should
be investigated if the regulation of synaptic function
operated by A depends on its transcriptional activity.
Recently Gatta and coworkers [32] performed a
microarray assay showing that exposure of neurob-
lastoma cells to an A42-Alluminum complex is
followed by a selective changes in gene expression.
This approach revealed that the activated genes are
involved in the modulation of calcium homeostasis,
glutamatergic transmission, oxidative stress, inflam-
mation and neuronal apoptosis [32].
It has been also reported that A peptides, in the
fibrillar form, exert their toxicity through the binding
to cell-surface holo-APP in cortical neurons [33]. In
our experiments, A42 upregulates BACE1 in APP
ko MEFs exactly as in wt or in PSdko MEFs. These
findings rule out APP as putative receptor for A,
at least in this conformation (soluble, not fibrillar) as
transducer for the modulation of BACE1. We have also
shown that the transcriptional activity promoted by
A42 on BACE1 is transmitted by the activation of
the JNK/c-jun pathway.
This pathway links all the pathological hallmarks of
AD: JNK activation has been reported to regulate the
phosphorylation of APP, leading to modulation of A
levels [34, 35], as well as to mediate the phosphoryla-
tion of tau in vitro [36]. Furthermore, the JNK pathway
is activated in preclinical models of AD, including
Tg2576 and Tg2576/PS1P264 L transgenic mice [37,
38], as well as in brains of AD cases [39–41].
Indeed, we have previously found a significant acti-
vation of JNK/AP1 in oxidative stress in vitro as well
as in vivo models, and the upregulation of BACE1 in
these models was not seen when JNK pathway had
been genetically or pharmacologically abolished [8].
It remains to be determined how A42 does activate
JNK pathway. A is known to alter intracellular cal-
cium homeostasis [42], and JNK could be activated
by the calcium/calmodulin dependent protein kinase
II (CAMKII) [43] or by a PI3K inducing signal, medi-
ated by calcium release [44]. Furthermore, it has been
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observed that A-induced increase in intracellular
calcium concentration stimulates BACE1 expression,
resulting in accelerated A generation, and that this
process is mediated by the calcineurin-NFAT1 signal-
ing pathway. NFAT1 is normally dephosphorylated by
calcium dependent manner by calcineurin, while it is
phosphorylated and inactivated by JNK [45].
Thereby, the interaction of A42 with multiple
receptors is likely to produce the activation of the
JNK/c-jun pathway. Different proteins, such as APP
itself, TrkA, p75NTR, NMDA, and AMPA receptors,
have been shown to interact directly or indirectly with
A peptides [46]. Moreover, LRP family of recep-
tors and apolipoprotein E, of which the 4 allele has
a strong linkage with AD, could represent a way for
A to enter into the cells [47, 48] and to activate the
signaling pathway that leads to BACE1 upregulation.
Being able to know the genes activated by A42
may be determinant to understanding the precise series
of events that cause dysfunction and degeneration of
neurons in AD. Moreover, to understand how A42
induces its own production by upregulating BACE1
expression would lead to new tools to interrupt the
amyloid vicious cycle, with potential therapeutic con-
sequences.
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